Woman of the Week: Myriad Genetics’ Nicole Lambert

Empowered by her own cancer journey, Nicole Lambert is using her platform as chief operating officer of the genetic testing powerhouse to change the trajectory of care for millions of women.

By Taren Grom • Nov. 23, 2022

How bacteria-enabled technology for wounds could also help cancer patients

Evelina Vågesjö, co-founder and CEO of the immunotherapy company Ilya Pharma, is working on a new modality to speed wound healing.

By Alexandra Pecci • Nov. 22, 2022

Explore the Trendline➔

Clinical trial diversity

As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.

By PharmaVoice staff

The next era of Greater Boston’s biotech boom

How Boston became the biotech capital of the U.S., and is now preparing for the next era of life sciences growth.  

By Karissa Waddick , Shaun Lucas , Julia Himmel • Nov. 22, 2022

In cancers with very low survival rates, Sellas aims higher

The company hopes its drugs can “take over where other available treatments fail” in multiple types of cancer.

By Kelly Bilodeau • Nov. 21, 2022

Is AI just hype or a real revolution in pharma? It’s complicated

Artificial intelligence can be a useful tool and will likely augment many processes in biopharma — but it's still early days, and hype is rampant.

By Michael Gibney • Nov. 17, 2022

To explore cancer’s genetic mysteries, researchers turn to ‘MACHETE’

A new CRISPR-based tool could help scientists understand and better treat cancer by revealing the complex genetic mutations that occur.

By Michael Gibney • Nov. 16, 2022

A ‘bold vision’ to prevent diabetes

Despite hearing that there’s “no money in prevention,” the CEO of Sigrid Therapeutics is forging ahead with the company’s goal of stopping Type 2 diabetes before it starts. 

By Alexandra Pecci • Nov. 15, 2022

4 ways to bring COVID’s ‘warp speed’ to the next era of drug development

An IQVIA Institute for Human Data Science report outlines how companies can improve communication, recruitment, data and investing strategies to accelerate clinical trial timelines.

By Kelly Bilodeau • Nov. 14, 2022

The legacy of Glen de Vries: Our last interview with the pioneering entrepreneur

Recorded just weeks before his passing, our sit-down interview with the legendary medical sciences entrepreneur showcased his passion for pushing the industry toward its next frontier.

By Taren Grom • Nov. 11, 2022

Novo Nordisk’s quantum bet on ‘world changing’ computing

Behind the pharma giant’s plans to build the first quantum computer by 2034 to accelerate drug development.

By Taren Grom • Nov. 10, 2022

Woman of the Week: 82VS’s Trier Bryant

Welcome to the Woman of the Week podcast, a weekly discussion that illuminates the unique stories of women leaders who are catalyzing change throughout the life sciences industry. You can check out all our podcast episodes here. Not every leader makes it their mission to go where the fire ...

By Taren Grom • Nov. 9, 2022

This plant-based gel stops bleeding in seconds — and might have potential in drug delivery

29-year-old biotech founder Joe Landolina is hoping to capitalize on major possibilities in the human health market through his startup Cresolin and just inked a research partnership with Walter Reed.

By Karissa Waddick • Nov. 9, 2022

While CAR-T wait times remain ‘heartbreaking,’ researchers push for innovations that could help

Facing an unprecedented manufacturing bottleneck, a new coalition is aiming to create the next generation of CAR-T therapies.

By Michael Gibney • Nov. 8, 2022

Chasing that ‘Time magazine cover potential’

Rami Elghandour was already retired. Then CAR-T specialist Arcellx lured him back into the industry to try to change the world.

By Alexandra Pecci • Nov. 8, 2022

After numerous setbacks, here’s where the Huntington’s pipeline stands

A look at emerging treatments and where there’s hope for patients.

By Kelly Bilodeau • Nov. 7, 2022

Acumen cruises into the fast lane with novel Alzheimer’s treatment

The company’s distinct amyloid-beta target, which just won a fast track designation, could give it an edge over the competition.

By Meagan Parrish • Nov. 3, 2022

‘Zombie’ cells, Shkreli and cats — new research in toxoplasmosis and how the three are connected

Toxoplasmosis is carried by about a third of the world’s population, but effective drugs are lacking — now researchers have discovered a key infection element that could lead to better treatment.

By Michael Gibney • Nov. 3, 2022

While DCTs get all the hype, some industry insiders say the future is a digital hybrid

Leaders at Veeva believe the wording around decentralized trials has been exaggerated, and that a bigger-picture outlook is important as the pandemic winds down.

By Michael Gibney • Nov. 1, 2022

Tuberculosis patients haven’t seen new treatments in 40 years – now Merck and Gates MRI have teamed up to change that

The Bill & Melinda Gates Medical Research Institute’s clinical development leader talks about its new licensing deal with Merck.

By Alexandra Pecci • Nov. 1, 2022

Tips for tackling trial recruitment and retention woes in oncology

How new tools are helping companies find and keep cancer patients in clinical studies.

By Kelly Bilodeau • Oct. 31, 2022

The first company to use Nobel-winning click chemistry in humans is on a mission to transform oncology

Shasqi founder and CEO José Mejía Oneto on how the company’s approach could provide a more effective alternative to ADCs and other emerging cancer therapies.

By Karissa Waddick • Oct. 27, 2022

Riches, rags, riches: Is Biogen the Cinderella of biotechs?

Biogen and Eisai's new Alzheimer's drug is wowing investigators, and it might help the companies get past previous failures.

By Michael Gibney • Oct. 27, 2022

Nobel Prize winner Carolyn Bertozzi on revealing the power of chemistry in drug development

The Stanford researcher and biotech entrepreneur discusses how click and bioorthogonal chemistry could revolutionize drug development.

By Karissa Waddick • Oct. 26, 2022

A longtime believer in mRNA, Strand Therapeutics’ co-founder is now pushing the tech to the next level

The company’s co-founder and head of R&D on how it’s using synthetic mRNA to create “smarter” therapies that could provide cures for cancer and more.

By Alexandra Pecci • Oct. 25, 2022

Beyond cancer: Scientists push CAR-T cell therapies into new frontiers

Why a ‘very exciting’ trial of the therapy in lupus patients could swing the door open to new studies in autoimmune diseases.

By Kelly Bilodeau • Oct. 24, 2022